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ABSTRACT 
OBJECTIVE 
To estimate the prevalence and causes of blindness and vision impairment for distance and 
near in Latin America and the Caribbean (LAC) in 2015, and to forecast trends to 2020. 
METHODS 
 A meta-analysis from a global systematic review of cross-sectional, population-representative 
studies from published and unpublished sources from 1980 to 2014 included in the Global 
Vision Database. 
RESULTS 
In 2015, across LAC, we estimate age-standardised prevalence to be 0.38% in all ages and 1.56% 
in those over age 50 for blindness, 2.06% in all ages and 7.86% in those over age 50 for 
moderate and severe vision impairment (MSVI), 1.89% in all ages and 6.93% in those over age 
50 for mild vision impairment, and 39.59% in all ages and 45.27% in those over 50 for near 
vision impairment.  We estimate that in 2015, 123.26 million persons were vision impaired; of 
those 2.34 million blind, 12.46 million with MSVI, 11.34 million mildly impaired and 97.12 
million had near vision impairment. Cataract is the most common cause of blindness. Under-
corrected refractive-error is the most common cause of vision impairment. 
CONCLUSIONS 
Increasing granularity in prevalence estimates across all levels of vision loss suggest that one in 
five persons across LAC had some degree of vision loss in 2015. The absolute numbers of 
persons with vision impairment are increasing, while the age-standardised prevalence is 
decreasing.  All countries should conduct epidemiologic studies to establish accurate national 
estimates and trends of vision impairment.  Universal eye health services must be included in 
universal health coverage reforms to address fragmentation and segmentation of health care 
across the region. 
KEYWORDS– prevalence, blindness, vision impairment, Latin America and Caribbean 
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INTRODUCTION 
 
The countries in Latin America and the Caribbean (LAC) global region have witnessed 
transformational health system reforms in moving toward universal health care since the 1980s 
and 1990s.
1, 2
 However, not all countries have transitioned to the same extent.  Health systems 
across the Americas are segmented by a mix of traditional public sector services for the poor, 
social security services for formal employees and their families, and private services for those 
who can afford it.  The rights granted, the coverage and the institutional organization and 
quality vary for different population groups, leading to fragmentation of care.  Both 
fragmentation and segmentation of health systems constitute important barriers to expanding 
coverage, achieving integrated primary health care, and reducing inefficiency and discontinuity 
of care.
3
 A study within Bogotá, Colombia, revealed a direct association between accessibility to 
health services and health status.
4
   
Visual and eye health status bear the consequences of this segmentation and fragmentation.  
We reported that in 2010, for every 100 persons in Latin America and Caribbean countries aged 
50 years and older, there were approximately 10 with moderate and severe vision impairment 
(visual acuity of <6/18 to ≥3/60), and two who were blind (visual acuity <3/60).
5
  The age-
standardized prevalence of blindness had halved from 0.8% to 0.4% between 1990 and 2010.
5
  
There was a reduction in vision loss resulting from cataract, which may reflect increased 
regional provision of cataract surgeries.
6
  Rising causes of vision loss included uncorrected 
refractive error, diabetic retinopathy, glaucoma and macular degeneration.
5
  We acknowledged 
the successful reduction of neglected tropical diseases in the region including onchocerciasis 
and trachoma.
5
  We expressed concern that the absolute numbers of persons blind or vision 
impaired may be rising due to ageing population demographics.
5
  As an example, the 
percentage of individuals aged 65 and above living in Latin America and the Caribbean rose 
from 4.75% in 1990 to 7.59% in 2015.
7
 
The demand for a reduction of blindness globally launched the ‘VISION 2020: The Right to Sight’ 
campaign in 1999 by the World Health Organization (WHO) and the International Agency for 
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the Prevention of Blindness (IAPB). This initiative challenged countries to eliminate avoidable 
blindness by the year 2020.
8
  In Latin America and the Caribbean, since 2004, the initiative has 
been driven as a partnership between the Pan American Health Organization (PAHO, 
representing WHO in the region), the IAPB, the Pan American Association of Ophthalmology 
representing local ophthalmological societies, and other non-governmental organizations. 
Building upon successes in the region, in 2014 the PAHO approved the Global Plan of Action for 
the Prevention of Blindness and Visual Impairment for 2014-2019.
9, 10
 This plan outlined steps 
to improve eye health of populations, including collecting epidemiological data, increasing 
coverage of high-quality eye care services, and minimizing barriers. The plan aims to further 
reduce the prevalence of avoidable vision impairment globally in 2019 by 25%, as compared to 
the 2010 baseline.  
The call to consistently apply globally comparable methodologies across and within regions to 
monitor the epidemiologic trends in blindness and vision impairment underpins the on-going 
work of the Vision Loss Expert Group within the Global Burden of Disease research group in the 
creation, analysis, and maintenance of a Global Vision Database 
(http://www.globalvisiondata.org/).
11, 12, 13, 14, 15
 Our 2010 study identified a paucity of 
population-based surveys, and of nationally representative surveys, in Latin America and the 
Caribbean region prior to 2010.
5, 13
 
The present report adds estimates for mild (visual acuity of <6/12 to ≥6/17) vision impairment 
and near vision impairment, and updates the previously published findings,
5
 to estimate the 
prevalence and causes of vision loss in Latin America and the Caribbean for 2015, five years 
before the target date of the VISION 2020 Initiative, with projection to 2020.   Projections will 
be important as the world moves toward the 2030 Agenda for Sustainable Development. The 
17 Sustainable Development Goals and 169 targets include issues that are related to eye and 
vision health, such as universal health care, poverty reduction, economic stability and decent 
work, gender equality and inclusive society.
16
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METHODS 
Consistent methodology to compare vision loss in regions and countries over time, gender and 
cause is the hallmark of outputs from the Global Vision Database (GVD). 
In accordance with the methodology utilized for the 2010 series estimating vision loss at the 
global, regional and country level,
13 
the present regional report for LAC utilises an identical 
methodology following the PRISMA guidelines as the global
 
all-cause 
14
 and cause-specific
15
 
estimates for 2015, which have been published in full elsewhere.
14, 15
  
In brief, we estimated 1990-2015 trends in vision impairment prevalence and their 
uncertainties, by age and gender, for 188 countries in the 21 Global Burden of Disease (GBD) 
regions using data in the Global Vision Database.
14
 The Latin America and Caribbean super-
region consists of five GBD regions: Caribbean, and Andean, Central, Southern and Tropical 
Latin America. The distribution of countries within these regions is presented in Table 1.  
Using definitions and an analytical framework developed and first described by Stevens et al,
13
 
we estimated the prevalence of two core categories of vision impairment: blindness (presenting 
visual acuity worse than 3/60) and combined moderate and severe vision impairment (MSVI) 
(presenting visual acuity worse than 6/18 but better than or equal to 3/60). We included 
distance vision impairment data from population-based studies identified through a systematic 
review using previously published search terms,
11
 including studies published between 1980 
and July 2014 and unpublished data identified by members of the Vision Loss Expert Group.  
We fitted two hierarchical Bayesian logistic regressions to estimate vision impairment 
prevalence over time - by age group, gender and country: one model for the prevalence of 
blindness and one model for the prevalence of MSVI. Using fully Bayesian statistical inference,
17
 
our posterior estimates of vision impairment were able to flexibly borrow strength, such that 
country-specific estimates were informed by study data from the same country, where 
available, and also by study data from other countries in the same region or the same year.  We 
modeled hierarchical linear trends over time, allowing for region-specific trends in prevalence 
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of vision impairment from world regions. Prevalence estimates are reported as posterior means 
along with 80% posterior uncertainty intervals (UI).  
We applied our model to forecast prevalence of blindness and MSVI into the future. Our model 
relies on health status and education as covariates. Since it is impossible to predict how these 
will evolve decades into the future, we extrapolated these covariates to the year 2020 and then 
held them constant to 2050. As our model gives estimates of crude prevalence for country-
years, we relied on the United Nations Population Division’s (UNPOP) forecasts to 2050 to 
derive crude numbers affected and age-standardized prevalence.
18
  
We estimated the causal proportions of overall vision impairment attributable to cataract, 
glaucoma, age-related macular degeneration, diabetic retinopathy, corneal opacity, trachoma, 
uncorrected refractive error, and non-cause specific/other causes in 1990–2015, by 
geographical region and year.
15
 We derived estimates of refractive error from the vision 
prevalence model described above, in which we explicitly modeled the contribution of 
refractive error to vision loss.  
To model each of the other causes, we separately fit Bayesian hierarchical logistic regression 
models, with covariates as follows: age group indicator, sex indicator, a linear year term, an 
indicator for best-corrected vs. presenting visual acuity, an indicator for blind vs. MSVI, an 
indicator for nationally representative data, an indicator for urban vs rural, and a health access 
covariate, which was also used for the prevalence data. Each observation in the model was at 
the level of a particular age group within a study. We included super region and study-level 
random effects.   
Each of our statistical models was fit with fully Bayesian inference through Markov Chain Monte 
Carlo sampling implemented in the probabilistic programming language Stan R.
19
 In order to 
combine the separate causal estimates, we used the overall prevalence estimates at the region 
level by year as an envelope. We used the refractive error estimates as derived from this 
model, and then apportioned the remaining prevalence to the various causes, normalizing so 
that these causes fit within the envelope.  
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RESULTS 
In the LAC combined region, we present model-based, age-standardized prevalence estimates 
by sex and geographic subregion within LAC, for all-ages and for adults 50 years and older.  
 
The global analysis included 283 studies,
14
 of which 23 studies (8.1%) were in the LAC region, 
representing 16 of 34 (47.1%) LAC countries (See Table 1). These included 17 (73.9%) published 
studies, and 6 unpublished data sets using the standardised Rapid Assessment of Avoidable 
Blindness or Cataract Surgery (RAAB/RAACS) protocol. Seven (30.4%) of the studies from the 
LAC region were nationally-representative, 3 (13.0%) were regionally-representative and 11 
(47.8 %) were locally-representative. These studies were undertaken between the years of 
1988 and 2014, and two, from Central Latin America, were newly added since the previous 
report.
5
  The majority of studies (n = 19, 82.6%) used the RAAB/RAACS protocol and included 
the population aged 50 years and above. The remaining studies included those aged 40 years 
and above (n = 1), 60 years and above (n = 1), all ages (n = 1), and school-aged children (n = 1). 
The sample size of the included studies ranged from 801 to 5284, with a mean of 3477 (SD 
1024) people. All 23 studies measured distance visual acuity, with 21 reporting both presenting 
and best-corrected acuity. Incidence data were available for studies in Barbados
20
 and Peru.  
 
In 2015 in the LAC region, the age-standardized prevalence of blindness in those over 50 years 
was 1.77 % and 0.43 % (80% UI 0.15-0.81) for all ages (Table 2).  In 2015 the prevalence of 
blindness in those over 50 years was slightly higher in women, at 1.82 % (80% UI 0.69-3.23), 
than men, at 1.70 % (80% UI 0.63-3.01).  The 2015 prevalence of MSVI was 2.78 % (80% UI 0.71-
5.60) in all ages, and 10.37 % (80% UI 2.94-20.48) in those over 50 years. 
 
The prevalence of mild distance vision impairment and presenting near vision impairment 
(presbyopia) by gender and age group for the regional level are herein estimated for the first 
time (Table 2). The prevalence of mild vision impairment was 2.37 % (80 %UI 0.55-4.93) in all 
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ages, and 8.13 % (80% UI 2.07-16.51) in those aged 50 years and above. The prevalence of 
presenting near vision impairment in 2015 in adults over 50 years was 45.27 % (80% UI 3.41–
93.38). 
 
Within the LAC region, the age-standardized prevalence of all categories of blindness and vision 
impairment was highest in the Latin American Andean region (Bolivia, Ecuador and Peru) with 
4.32 % (80% UI 1.26-8.4) MSVI in all ages, and lowest in the Latin American Tropical (Brazil and 
Paraguay) and Southern (Argentina, Chile and Uruguay) regions, with 2.21 % (80% UI 0.50-4.67) 
and 2.71 % (80% UI 0.70 – 5.47), respectively (Table 3). In adults over 50 years, the age-
standardized prevalence of blindness for both sexes was greatest in Guatemala and lowest in 
Argentina (Figure 1). The age-standardized prevalence of MSVI in those over 50 years was 
lowest in Brazil and highest in Haiti (Figure 2). Compared to the global mean prevalence 
estimate for blindness in those aged over 50 years, of 1.87 % (80% UI 0.67 - 3.39), the 
prevalence was estimated to be higher in the Caribbean and in Andean Latin America, but lower 
elsewhere in LAC.  The prevalence of MSVI and mild vision impairment in those over 50 years 
was generally lower in LAC regions than the global average, with the exception of Andean Latin 
America, where it was higher. The same regional variation compared to the global mean was 
observed in the data by region for all ages (Table 3).   
  
In 2015 the total number of blind persons in the LAC region was estimated to be 2.34 million, 
ranging from 0.22 million in the Caribbean to 0.96 million in Central Latin America. This 
represents 6.4% of the total number of blind people globally (Table 4). The total number of 
moderate and severe vision impaired persons in the LAC region was estimated at 12.46 million, 
ranging from 0.90 million in the Caribbean to 4.84 million in Central Latin America, which 
represents 5.7% of the total number globally. The total number of persons with mild vision 
impairment was estimated at 11.34 million, ranging from 0.80 million in the Caribbean to 4.37 
million in Central Latin America, representing 6.0% of those globally.  The total number of 
persons with near vision impairment in LAC was estimated at 91.72 million, ranging from 3.28 
million in Southern Latin America to 36.97 million in Central Latin America, representing 8.4% of 
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those globally (see Table 4). Summing these for 2015 resulted in an estimated 123.26 million 
persons in LAC living with some degree of vision loss.  This translates to approximately one in 
five persons in the region.  These numbers are projected to increase to a small extent for each 
category of vision loss by 2020 (Table 4). 
 
The Proportion of blindness, and vision impairment (MSVI) by cause in 2015 for all ages is 
shown in Table 5.   
Cataract continues to cause the largest proportion of blindness in 2015 across all LAC regions, 
varying from 21.8% (80% UI 13.89-30.16) in Southern Latin America to 25.73% (80% UI 18.66-
32.95) in the Caribbean.  In every region except Southern Latin America, the second most 
frequent cause of blindness was under-corrected refractive error (UCRE), followed by 
glaucoma, then macular degeneration, then corneal opacity, and diabetic retinopathy was the 
sixth most common cause.  In Southern Latin America, however, after cataract (21%, 80% UI 
13.89-30.16), the subsequent most frequent causes of blindness were macular degeneration 
(14.34%, 80% UI 3.98-28.6) followed by glaucoma (13.34%, 80% UI 4.67-25.0), UCRE (13%, 80% 
UI 11.27-14.71), diabetic retinopathy (3.51%, 80% UI 0.51-8.08) and then corneal opacity 
(2.41%, 80% UI 0.19-5.85). While the global figures apportion 24.92% to other causes, LAC 
attributes between 31.45% (Southern Latin America) and 44.66% (Andean Latin America) to 
other causes, suggesting that the leading causes of blindness determined by surveys are 
becoming more diverse.  
Nearly half (Andean 46.07% to Tropical 49.26%) of all MSVI can be attributed to under-
corrected refractive error, making this a priority for intervention in LAC.  Cataract is the second 
most common cause (Tropical 15.27% to 20.23% Andean) in all regions.  Exceptionally, 
Southern Latin America had a very high proportion of macular degeneration (10.11%, 80% UI 
2.78-20.18) in third place, almost four times higher than Andean Latin America (2.44%, 80% UI 
0.47-5.27).  The remaining causes of MSVI varied in proportion from region to region with 
regard to glaucoma vs. AMD, and DR was usually the fifth most common cause followed by 
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corneal opacity.  These rankings are projected to change very little in 2020 even though the 
exact proportions might shift slightly.   
 
 
DISCUSSION 
 
The primary objective of this study was to present regional estimates of the prevalence and 
causes of blindness and vision impairment for distance and near in Latin America and the 
Caribbean (LAC) in 2015, with a secondary objective to model projected trends to 2020. To 
accomplish this, we undertook a systematic review of cross-sectional, population-
representative studies from published and unpublished sources, and extracted data for meta-
analysis.  
This analysis had a number of limitations. Firstly, the number, type and frequency of studies 
available for inclusion in the LAC model deserves analysis.  The systematic review identified 
population-representative surveys from 13 out of 17 (76%) countries in Latin America, but only 
3 out of 17 (18%) countries in the Caribbean.  The majority of surveys (78%) in the LAC region 
were based on the rapid assessment of avoidable blindness (RAAB) protocol. Limitations of this 
survey protocol include age restriction to those over 50 years, and those available at the time of 
screening, and cause attribution sometimes based on non-dilated examination with a direct 
ophthalmoscope, which may introduce diagnostic bias in cause attribution favoring cataract 
over posterior segment disease. Near vision impairment is not yet included in this protocol, and 
only recently was mild vision impairment included. The majority of surveys in the LAC region 
(70%) were not nationally representative. Potential bias could arise if there is regional variation 
within countries in the prevalence of blindness and vision impairment. 74% of the included 
studies were published, with a detailed outline of survey methodology available for scrutiny. 
Additional data from unpublished RAAB studies utilising standardised methodology was 
included, aiming to increase the power and representativeness of the model estimates. The 
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end-date for the search was July 2014, and we acknowledge that other studies will have been 
published since, which will be added to subsequent updates from the Global Vision Database.  
This review has identified a particular need for epidemiological surveys in every country in the 
Caribbean region, and in Latin America in particular, in Colombia, Costa Rica, Nicaragua and 
Bolivia. In addition, new nationally representative studies are needed in countries whose data 
were obtained over 10 years ago, in order to update and facilitate more reliable temporal trend 
analysis.  Future surveys should include measurement of mild and near vision impairment, as 
the latter has been recognised to have a significant economic and quality of life impact, at both 
individual and societal levels.
21
 Furthermore, there was a marked paucity of data from younger 
age groups, with only 2 studies including people under 40 years. This problem is not specific to 
studies from the LAC region, and relates to challenges designing surveys of blindness in children 
and young people, for whom much larger sample sizes are required, along with specialised 
expertise and equipment, available to few surveys.  
 
Overall, the LAC regional and country estimates for the age-standardized prevalence of 
blindness, mild vision impairment, MSVI and presbyopia have progressively become more 
described for the time period between 1990 and 2015. This may be the result of well-planned 
and well-executed programs and research conducted through WHO VISION 2020 and local 
Ministries of Health, and academic or other institutions. It is important to consider that with the 
increasing size and age of the population, the absolute numbers with vision loss in the region 
are substantial, with non-blinding vision impairment increasing.  While we previously estimated 
that the prevalence of blindness had halved from 1990 to 2010,
5
 our projections to 2020 
predict only a slight reduction in the prevalence of avoidable blindness from 2015, implying that 
the region may fall short of the PAHO and WHO goal of a 25% reduction in avoidable blindness 
by 2020. Efforts could be intensified during the 2014-2019 action plan years to achieve this 
goal. Due to the aging population, the absolute number of people with vision loss continues to 
be a major public health concern in LAC. 
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The causes of vision loss in LAC are diversifying, with important causes falling under our largest 
category of ‘other’.  The proportion of the category of ‘other’ causes across LAC regions 
averaged approximately double that of the global proportion of ‘other’ causes in 2015.  It is 
imperative to explore and document the prevalence of these other causes in order to consider 
the interventions necessary to address them.
22
 Even with the most common cause of blindness, 
cataract, interventions such as cataract surgery have variable coverage and variable vision 
outcomes, which may be exacerbated by fragmented health care systems and more limited 
access to eye care in rural areas.
23
 There is variability in whether the service is provided in the 
public hospital, by a private physician, a non-governmental organization or a visiting surgeon as 
well as variability in output and cataract surgical coverage rates. Costs borne by the patient 
range from zero to the full market price, and there are multiple barriers to accessing care.  For 
example, higher levels of wealth, literacy and schooling have been associated with successfully 
obtaining cataract surgery, and improved surgical outcome.
24
 In common with the wider health 
services in low, middle, and even high-income countries, eye care services are constrained by 
shortages and unequal distribution of appropriately qualified staff and specialised equipment, 
weak systems for planning and management, and bureaucracy.
24, 25
  
 
Refractive error and cataract are considered treatable causes of vision impairment and may be 
considered avoidable.  Together in 2015 they comprised approximately 36% of all cases of 
blindness, but 65.5% of all cases of MSVI in the region. By 2020 the proportion of cases of vision 
impairment caused by cataract and refractive error is projected to decrease another 2%. Hence, 
there is a need for further effort to reduce cataract-related blindness. The recognition of the 
importance of near vision impairment, and under-corrected distance refractive error 
encompassing a larger proportion of vision loss indicates the need for increased attention on 
refractive error correction.  If refractive error can be properly addressed by the year 2020, 
further major advances in the reduction of vision impairment could be gained. 
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In contrast to the previous prevalence estimates presented in the 2010 study, which reported 
95% confidence intervals,
5
 this study presents 80% uncertainty intervals. We believe these 
Bayesian summaries of posterior distribution give a more accurate description of our posterior 
uncertainty than the more commonly used 95% confidence interval. An important limitation of 
this meta-analysis, reflected in the wide uncertainty intervals for the prevalence estimates, is 
the paucity of data from some sub-regions, and particularly the lack of nationally-
representative data from countries within the LAC region, as reflected in Table 1. This resulted 
in the use of covariates for the super-region, which may explain why, in some GBD regions, the 
cause proportions estimated differ from the actual local or sub-national survey published 
reports.
24
  As described in the introduction,
3
 the fragmentation and segmentation of eye health 
systems between and within countries may explain why the use of super-region estimates may 
not necessarily reflect actual prevalence in a specific country or sub-national locale.  All 
member states within the LAC region have signed up to the regional and global action plans and 
strategies advocated by the PAHO and WHO, which aim to reduce the burden of avoidable 
blindness and vision impairment. However, there has been less than expected progress in terms 
of the collection of epidemiological data since our last study reported data up to 2010. There 
was a particular lack of data on near vision impairment, reflected in the very wide uncertainty 
intervals, and it was not possible to disaggregate by severity of near vision impairment.  
Countries may need further encouragement with respect to the importance of both collecting 
epidemiological data, and reporting it in a timely fashion.  
Future studies should examine specific coverage of eye and vision services within the health 
systems by each country in LAC, and also examine which specific factors are used to monitor 
and to evaluate eye care programs in different geographic areas and countries. This may be 
especially useful in the Latin American Andean region, Central region and the Caribbean, which 
differ markedly in terms of prevalence estimates, from Southern Latin America. Disparities may 
be indicative of fragmented health and eye care systems, but further investigation should 
uncover possible causes and more importantly indicate solutions for these 
differences.  Furthermore, continual, accurate and comprehensive data are needed to evaluate 
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and eliminate disparities in the region. The increasing numbers of older persons, coupled with 
the increase in vision loss associated with older age, will require further intervention if 
continued reduction in both prevalence and absolute numbers of blind persons are to be seen 
in the LAC region and globally. 
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TABLE 3: Age-standardized prevalence of blindness and vision impairment (and 80% uncertainty 
interval) by sex and region comparing adults 50 years and older with all ages in 2015 
TABLE 4: Absolute numbers of persons affected by blindness and vision impairment in Latin 
American and the Caribbean in 2015 and projections to 2020 
TABLE 5: Proportion of blindness, and vision impairment (MSVI) by cause in 1990, 2010, 2015 
and projected to 2020 for all ages (80% uncertainty interval) 
FIGURE 1: Ladder plot showing the age-standardised prevalence of blindness in women (A) and 
men (B) aged 50+ years for 2015 by country 
FIGURE 2: Ladder plot showing the age-standardised prevalence of moderate/severe vision 
impairment (MSVI) in women (A) and men (B) aged 50+ years for 2015 by country 
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TABLE 1:  Countries in Latin America and the Caribbean by region 
 Region Countries 
Caribbean Antigua and Barbuda, Bahamas, Barbados*, Belize, 
Bermuda, Cuba*, Dominica, Dominican Republic*, 
Grenada, Guyana, Haiti, Jamaica, Puerto Rico, Saint Lucia, 
Saint Vincent and the Grenadines, Suriname, Trinidad and 
Tobago  
Latin America, Andean Bolivia, Ecuador*, Peru* 
Latin America, Central Colombia, Costa Rica, El Salvador*, Guatemala*, 
Honduras*, Mexico*, Nicaragua, Panama*, Venezuela* 
Latin America, Southern Argentina*, Chile*, Uruguay* 
Latin America, Tropical Brazil* and Paraguay* 
*Those for which data were available are marked with an asterisk. 
A list of all references used for this analysis can be found in a web appendix at http:// 
www.anglia.ac.uk/verugbd. 
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TABLE 2: Age-standardised prevalence of blindness and vision impairment by sex for those aged 50 and older and all ages in 
Latin America and the Caribbean in 2015 and projected to 2020 
 
2015 OVER 50 ALL AGES 
 
2020   OVER 50 ALL AGES 
Vision Impairment 
Category Sex Mean (80% UI) Mean (80% UI)   Sex Mean (80% UI) Mean (80% UI) 
Blindness 
 Male 1.55 (0.56 - 2.77) 0.38 (0.14 - 0.68) 
 
Male 1.34 (0.46 - 2.45) 0.33 (0.11 - 0.60) 
 
Female 1.58 (0.56 - 2.84) 0.39 (0.14 - 0.70) 
 
Female 1.36 (0.46 - 2.51) 0.33 (0.11 - 0.61) 
 
Both 1.56 (0.56 - 2.81) 0.38 (0.14 - 0.69) 
 
Both 1.35 (0.46 - 2.48) 0.33 (0.11 - 0.61) 
Moderate + Severe (MSVI)           
 
Male 7.75 (3.31 - 13.21) 2.04 (0.85 - 3.50) 
 
Male 7.10 (2.82 - 12.35) 1.86 (0.72 - 3.27) 
 
Female 7.96 (3.30 - 13.66) 2.09 (0.84 - 3.62) 
 
Female 7.27 (2.81 - 12.73) 1.91 (0.72 - 3.36) 
 
Both 7.86 (3.30 - 13.46) 2.06 (0.85 - 3.56) 
 
Both 7.19 (2.81 - 12.56) 1.89 (0.72 - 3.32) 
Mild               
 
Male 6.85 (2.34 - 12.81) 1.87 (0.61 - 3.56) 
 
Male 6.35 (2.02 - 12.13) 1.73 (0.52 - 3.35) 
 
Female 6.99 (2.36 - 13.12) 1.91 (0.61 - 3.64) 
 
Female 6.48 (2.04 - 12.40) 1.76 (0.52 - 3.42) 
 
Both 6.93 (2.35 - 12.98) 1.89 (0.61 - 3.60) 
 
Both 6.42 (2.03 - 12.28) 1.75 (0.52 - 3.39) 
Near               
 
Both 45.27 (3.41 - 93.38) 39.59 (2.59 - 88.12) 
 
Both 45.27 (3.40 - 93.37) 39.59 (2.59 - 88.11) 
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TABLE 3:  Age-standardised prevalence of blindness and vision impairment (and 80% UI) by sex and region comparing adults 50 years and older with all ages in 2015 
 
Ages 50+ 
Men Women Both 
Region Blind MSVI Mild Blind MSVI Mild Blind MSVI Mild 
Caribbean 
1.96 (0.68 - 
3.56) 7.92 (3.32 - 13.60) 
6.87 (2.33 - 
13.05) 
2.07 (0.69 - 
3.80) 
8.25 (3.29 - 
14.37) 
7.05 (2.33 - 
13.44) 
2.02 ( 0.07 - 
3.69)  
8.09 (3.30 - 
14.00) 
6.96 (2.32 - 
13.2) 
Andean 
2.15 (0.73 - 
3.97) 
12.39 (5.87 - 
20.46) 
9.96 (3.80 - 
17.88) 
2.28 (0.77 - 
4.25) 
13.05 (6.04 - 
21.64) 
10.28 (3.87 - 
18.42) 
2.22 (0.08 - 
4.12) 
12.74 (5.96 - 
21.09) 
10.13 (3.83 - 
18.16) 
Central 
1.79 (0.65 - 
3.15) 8.47 (3.66 - 14.26) 
7.35 (2.55 - 
13.63) 
1.85 (0.66 - 
3.29) 
8.67 (3.61 - 
14.82) 
7.48 (2.55 - 
13.85) 
1.82 (.066 - 
3.23) 
8.58 (3.63 - 
14.56) 
7.42 (2.56 - 
13.74) 
Southern 
0.71 (0.31 - 
1.22) 6.58 (3.12 - 11.01) 
6.25 (2.25 - 
11.70) 
0.78 (0.34 - 
1.34) 
7.35 (3.52 - 
12.28) 
6.85 (2.51 - 
12.73) 
0.75 (0.32 - 
1.29) 
7.02 (3.36 - 
11.73) 
6.58 (2.40 - 
12.27) 
Tropical 
1.40 (0.49 - 
2.52) 6.30 (2.38 - 11.16) 
5.83 (1.82 - 
11.17) 
1.42 (0.49 - 
2.58) 
6.35 (2.29 - 
11.26) 
5.85 (1.78 - 
11.37) 
1.41 (0.04 -
2.5) 
6.33 (2.33 - 
11.22) 
5.84 (1.80 - 
11.28) 
World 
1.82 (0.67 - 
3.28) 
10.12 (4.85 - 
16.45) 
8.33 (3.10 - 
15.02) 
1.91 (0.68 - 
3.49) 
10.79 (5.00 - 
17.74) 
8.77 (3.23 - 
15.84) 
1.87 (0.67 - 
3.39) 
10.47 (4.93 - 
17.13) 
8.56 (3.17 - 
15.45) 
All ages 
Men Women Both 
Region Blind MSVI Mild Blind MSVI Mild Blind MSVI Mild  
Caribbean 
0.49 (0.17 - 
0.89) 2.12 (0.86 - 3.68) 1.93 (0.61 - 3.73) 
0.51 (0.17 - 
0.94) 2.21 (0.85 - 3.89) 
1.98 (0.61 - 
3.84) 
0.50 (0.17 - 
0.92) 
2.16 (0.86 - 
2.79) 
1.95 (0.61 - 
3.78) 
Andean 
0.52 (0.18 - 
0.97) 3.30 (1.51 - 5.52) 2.82 (1.00 - 5.22) 
0.55 (0.19 - 
1.04) 3.46 (1.55 - 5.83) 
2.91 (1.01 - 
5.38) 
0.54 (0.18 - 
1.00) 
3.38 (0.15 - 
5.68) 
2.86 (1.00 - 
5.30) 
Central 
0.44 (0.16 - 
0.77) 2.22 (0.94 - 3.76) 2.00 (0.66 - 3.79) 
0.45 (0.16 - 
0.80) 2.27 (0.92 - 3.91) 
2.04 (0.65 - 
3.84) 
0.45 (0.16 - 
0.79) 
2.24 (0.92 -
3.84) 
2.02 (0.66 - 
3.81) 
Southern 
0.17 (0.07 - 
0.30) 1.71 (0.80 - 2.89) 1.67 (0.57 - 3.17) 
0.19 (0.08 - 
0.33) 1.91 (0.90 - 3.22) 
1.83 (0.64 - 
3.47) 
0.18 (0.08 - 
0.31) 
1.82 (0.86 -
3.08) 
1.75 (0.61 - 
3.33) 
Tropical 
0.34 (0.12 - 
0.61) 1.64 (0.61 - 2.92) 1.56 (0.47 - 3.03) 
0.35 (0.12 - 
0.63) 1.65 (0.58 - 2.94) 
1.56 (0.45 - 
3.06) 
0.34 (0.12 - 
0.62) 
1.64 (0.59 - 
2.93) 
1.56 (0.46 - 
3.04) 
World 
0.46 (0.17 - 
0.84) 2.79 (1.29 - 4.61) 2.46 (0.84 - 4.55) 
0.49 (0.17 - 
0.90) 2.99 (1.33 - 4.99) 
2.60 (0.88 - 
4.85) 
0.48 (0.17 - 
0.87) 
2.90 (1.31 - 
4.80) 
2.53 (0.86 
4.70) 
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TABLE 4: Absolute numbers of persons affected by blindness and vision impairment in Latin American and the Caribbean in 
2015 and projections to 2020 
Region Blind (millions)  MSVI (millions) Mild (millions) Near (millions) 
2015 
Caribbean 0.22 (0.07 - 0.40) 0.90 (0.36 - 1.57) 0.80 (0.25 - 1.54) 6.56 (0.68 - 14.04) 
Latin America, Andean 0.27 (0.09 - 0.51) 1.70 (0.77 - 2.86) 1.44 (0.50 - 2.67) 8.24 (0.87 - 17.68) 
Latin America, Central 0.96 (0.34 - 1.70) 4.84 (2.00 - 8.29) 4.37 (1.40 - 8.28) 36.97 (3.65 - 79.79) 
Latin America, Southern 0.17 (0.07 - 0.29) 1.53 (0.74 - 2.56) 1.43 (0.52 - 2.66) 3.28 (0.75 - 6.90) 
Latin America, Tropical 0.72 (0.25 - 1.30) 3.49 (1.26 - 6.22) 3.33 (0.97 - 6.51) 36.67 (3.72 - 77.77) 
Combined Total LAC 2.34 (0.82 - 4.20) 12.46 (5.13 - 21.5) 11.34 (3.64 - 21.66) 91.72 (9.67 - 196.18) 
World 36.02 (12.86 - 65.44) 216.60 (98.51 - 359.07) 188.54 (64.46 - 350.19) 1094.75 (581.13 - 1686.54) 
2020 
Caribbean 0.22 (0.07 - 0.41) 0.95 (0.35 - 1.69) 0.85 (0.25 - 1.66) 7.17 (0.75 - 15.29) 
Latin America, Andean 0.28 (0.09 - 0.53) 1.84 (0.78 - 3.14) 1.56 (0.52 - 2.94) 9.46 (1.00 - 20.26) 
Latin America, Central 1.00 (0.34 - 1.81) 5.27 (2.02 - 9.15) 4.78 (1.44 - 9.16) 42.56 (4.23 - 91.52) 
Latin America, Southern 0.17 (0.07 - 0.30) 1.63 (0.75 - 2.78) 1.52 (0.53 - 2.86) 3.58 (0.82 - 7.55) 
Latin America, Tropical 0.72 (0.23 - 1.35) 3.67 (1.23 - 6.68) 3.52 (0.95 - 7.02) 41.58 (4.21 - 88.20) 
Combined Total LAC 2.39 (0.80 - 4.40) 13.36 (5.13 - 23.44) 12.23 (3.69 - 23.64) 104.35 (11.01 - 222.82) 
World 38.50 (13.18 - 70.95) 237.08 (101.50 - 399.02) 205.73 (67.30 - 385.11) 1225.59 (653.43 - 1884.22) 
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TABLE 5: Proportion (%) of blindness, and moderate/severe vision impairment (MSVI) by cause in 1990, 2010, 2015 and projected to 2020 for all ages (80% Uncertainty Interval)
Region
1990 Blind MSVI Blind MSVI Blind MSVI Blind MSVI Blind MSVI Blind MSVI Blind MSVI 
Caribbean 12.37 (10.48 - 14.21) 46.74 (42.23 - 50.32) 29.42 (23.42 - 35.36) 21.47 (16.96 - 26.14) 10.56 (4.07 - 18.89) 2.55 (0.84 - 4.89) 8.50 (2.26 - 17.34) 5.75 (1.35 - 12.07) 0.68 (0.13 - 1.47) 0.77 (0.15 - 1.60) 2.62 (0.26 - 6.37) 0.88 (0.08 - 2.03) 35.83 (18.24 - 52.15) 21.81 (8.56 - 35.80)
Andean 12.40 (10.50 - 14.26) 44.63 (38.93 - 49.12) 32.66 (26.42 - 38.79) 24.91 (19.98 - 29.97) 10.15 (3.84 - 18.29) 2.45 (0.81 - 4.76) 4.92 (1.00 - 10.71) 3.24 (0.59 - 7.17) 0.29 (0.05 - 0.61) 0.32 (0.05 - 0.66) 2.63 (0.27 - 6.44) 0.94 (0.09 - 2.16) 36.95 (18.84 - 53.71) 23.51 (9.29 - 38.45)
Central 12.39 (10.51 - 14.20) 46.39 (42.01 - 50.06) 30.15 (24.11 - 36.09) 22.34 (17.72 - 27.05) 10.46 (4.06 - 18.61) 2.51 (0.85 - 4.81) 7.19 (1.74 - 15.13) 4.70 (0.99 - 10.08) 0.53 (0.10 - 1.14) 0.58 (0.11 - 1.19) 2.65 (0.28 - 6.46) 0.90 (0.09 - 2.07) 36.63 (18.72 - 53.16) 22.59 (8.90 - 36.99)
Southern 12.91 (11.18 - 14.64) 47.75 (44.69 - 50.33) 27.07 (20.39 - 34.03) 20.63 (15.36 - 26.27) 14.00 (5.80 - 23.99) 3.74 (1.35 - 7.01) 15.72 (5.59 - 28.89) 10.98 (3.56 - 21.00) 2.08 (0.46 - 4.26) 2.16 (0.51 - 4.46) 3.39 (0.34 - 8.17) 1.19 (0.13 - 2.71) 24.83 (10.73 - 41.56) 13.55 (4.79 - 24.07)
Tropical 12.72 (10.91 - 14.47) 48.34 (44.91 - 51.06) 28.39 (22.62 - 34.18) 20.42 (16.14 - 24.87) 10.88 (4.29 - 19.26) 2.53 (0.86 - 4.82) 7.70 (1.89 - 16.08) 4.95 (1.07 - 10.59) 0.75 (0.15 - 1.63) 0.77 (0.15 - 1.58) 2.51 (0.27 - 6.01) 0.84 (0.09 - 1.92) 37.05 (18.93 - 53.77) 22.16 (8.76 - 36.23)
World 19.58 (17.29 - 21.72) 50.80 (46.12 - 54.74) 36.67 (30.11 - 43.22) 26.62 (21.53 - 31.78) 8.66 (3.25 - 15.72) 2.14 (0.69 - 4.11) 7.93 (2.32 - 15.54) 5.97 (1.63 - 11.87) 0.85 (0.15 - 1.83) 1.03 (0.20 - 2.22) 4.75 (0.80 - 10.47) 1.75 (0.25 - 3.81) 18.78 (7.12 - 32.87) 9.71 (3.03 - 18.50)
2010
Caribbean 12.55 (10.73 - 14.33) 47.64 (44.17 - 50.48) 26.84 (20.18 - 33.56) 19.04 (14.26 - 24.00) 9.71 (3.56 - 17.58) 2.27 (0.73 - 4.27) 6.08 (1.47 - 12.60) 4.07 (0.91 - 8.68) 0.73 (0.14 - 1.55) 0.82 (0.17 - 1.71) 1.77 (0.18 - 4.22) 0.56 (0.06 - 1.32) 42.31 (21.64 - 61.34) 25.60 (10.06 - 41.96)
Andean 12.58 (10.77 - 14.37) 45.80 (41.40 - 49.37) 28.75 (21.97 - 35.58) 21.31 (16.21 - 26.59) 9.56 (3.59 - 17.13) 2.25 (0.76 - 4.17) 4.11 (0.89 - 8.66) 2.62 (0.54 - 5.63) 0.36 (0.06 - 0.75) 0.39 (0.08 - 0.81) 1.73 (0.18 - 4.14) 0.57 (0.07 - 1.31) 42.92 (21.86 - 62.44) 27.06 (10.62 - 44.39)
Central 12.66 (10.88 - 14.42) 47.67 (44.42 - 50.41) 25.21 (18.88 - 31.66) 18.07 (13.52 - 22.89) 10.12 (3.83 - 18.05) 2.37 (0.78 - 4.42) 6.48 (1.57 - 13.47) 4.16 (0.92 - 8.90) 0.83 (0.16 - 1.74) 0.89 (0.18 - 1.83) 1.73 (0.18 - 4.07) 0.55 (0.06 - 1.29) 42.97 (21.99 - 62.33) 26.28 (10.34 - 43.06)
Southern 12.98 (11.25 - 14.69) 48.06 (45.23 - 50.38) 23.12 (15.66 - 31.09) 17.20 (11.76 - 23.22) 13.76 (5.13 - 24.60) 3.72 (1.20 - 7.16) 14.49 (4.43 - 28.05) 10.23 (3.11 - 20.00) 2.97 (0.50 - 6.58) 3.30 (0.58 - 7.27) 2.52 (0.22 - 6.04) 0.86 (0.09 - 2.05) 30.17 (13.06 - 50.33) 16.64 (5.86 - 29.57)
Tropical 12.88 (11.13 - 14.60) 49.17 (46.60 - 51.28) 22.99 (17.07 - 29.13) 16.13 (11.94 - 20.60) 10.62 (4.03 - 18.95) 2.44 (0.79 - 4.59) 7.79 (1.92 - 16.12) 4.94 (1.11 - 10.61) 1.26 (0.25 - 2.65) 1.30 (0.27 - 2.67) 1.64 (0.17 - 3.83) 0.52 (0.06 - 1.22) 42.80 (21.80 - 62.28) 25.50 (10.01 - 41.85)
World 20.23 (18.16 - 22.20) 52.12 (48.44 - 55.23) 35.67 (27.74 - 43.66) 25.55 (19.80 - 31.54) 8.48 (3.17 - 15.38) 2.04 (0.66 - 3.93) 6.28 (1.68 - 12.64) 4.65 (1.21 - 9.53) 0.99 (0.16 - 2.19) 1.21 (0.21 - 2.68) 3.37 (0.58 - 7.39) 1.19 (0.19 - 2.55) 23.43 (8.98 - 40.83) 12.17 (3.87 - 23.03)
2015
Caribbean 12.59 (10.78 - 14.37) 47.85 (44.44 - 50.66) 25.74 (18.66 - 32.95) 18.09 (13.08 - 23.36) 9.61 (3.32 - 17.76) 2.25 (0.68 - 4.30) 5.64 (1.25 - 11.90) 3.76 (0.78 - 8.16) 0.79 (0.13 - 1.70) 0.89 (0.16 - 1.90) 1.65 (0.15 - 3.91) 0.52 (0.05 - 1.23) 43.98 (22.57 - 63.65) 26.64 (10.50 - 43.58)
Andean 12.62 (10.82 - 14.41) 46.07 (41.71 - 49.60) 27.48 (20.20 - 34.81) 20.23 (14.87 - 25.82) 9.40 (3.33 - 17.26) 2.22 (0.70 - 4.16) 3.84 (0.78 - 8.18) 2.44 (0.47 - 5.27) 0.39 (0.06 - 0.83) 0.42 (0.07 - 0.89) 1.60 (0.16 - 3.82) 0.53 (0.06 - 1.22) 44.66 (22.83 - 64.82) 28.09 (11.05 - 46.03)
Central 12.71 (10.93 - 14.46) 47.90 (44.70 - 50.60) 23.97 (17.25 - 30.90) 17.03 (12.25 - 22.14) 9.99 (3.56 - 18.25) 2.34 (0.72 - 4.46) 6.19 (1.38 - 13.07) 3.96 (0.82 - 8.60) 0.95 (0.16 - 2.03) 1.02 (0.19 - 2.14) 1.62 (0.16 - 3.83) 0.52 (0.05 - 1.21) 44.58 (22.85 - 64.57) 27.23 (10.72 - 44.58)
Southern 13.00 (11.27 - 14.71) 48.20 (45.38 - 50.51) 21.68 (13.89 - 30.16) 15.95 (10.40 - 22.13) 13.61 (4.67 - 25.00) 3.71 (1.09 - 7.35) 14.34 (3.98 - 28.60) 10.11 (2.78 - 20.18) 3.51 (0.51 - 8.08) 3.93 (0.60 - 8.97) 2.41 (0.19 - 5.85) 0.82 (0.07 - 1.96) 31.45 (13.62 - 52.38) 17.28 (6.09 - 30.72)
Tropical 12.90 (11.14 - 14.62) 49.26 (46.68 - 51.36) 21.88 (15.57 - 28.47) 15.27 (10.84 - 20.04) 10.45 (3.72 - 19.07) 2.41 (0.73 - 4.62) 7.39 (1.68 - 15.61) 4.68 (0.98 - 10.20) 1.33 (0.24 - 2.87) 1.38 (0.26 - 2.90) 1.54 (0.15 - 3.60) 0.49 (0.05 - 1.14) 44.50 (22.78 - 64.56) 26.52 (10.43 - 43.45)
World 20.28 (18.23 - 22.24) 52.34 (48.66 - 55.45) 35.15 (26.40 - 44.03) 25.15 (18.83 - 31.76) 8.49 (2.99 - 15.66) 2.05 (0.62 - 4.03) 5.93 (1.46 - 12.18) 4.38 (1.05 - 9.15) 1.06 (0.15 - 2.38) 1.30 (0.20 - 2.93) 3.21 (0.50 - 7.19) 1.14 (0.17 - 2.48) 24.92 (9.58 - 43.36) 13.00 (4.14 - 24.57)
2020
Caribbean 12.64 (10.83 - 14.42) 48.08 (44.72 - 50.89) 24.41 (16.89 - 32.10) 16.96 (11.69 - 22.60) 9.52 (3.02 - 18.11) 2.24 (0.62 - 4.43) 5.61 (1.13 - 12.13) 3.79 (0.71 - 8.44) 0.98 (0.14 - 2.15) 1.13 (0.18 - 2.43) 1.55 (0.13 - 3.68) 0.49 (0.04 - 1.16) 45.29 (23.19 - 65.61) 27.31 (10.73 - 44.77)
Andean 12.68 (10.88 - 14.47) 46.44 (42.08 - 49.95) 25.88 (18.18 - 33.74) 18.85 (13.21 - 24.79) 9.37 (3.09 - 17.57) 2.22 (0.66 - 4.31) 3.84 (0.72 - 8.30) 2.45 (0.44 - 5.40) 0.47 (0.07 - 1.03) 0.52 (0.08 - 1.11) 1.52 (0.14 - 3.64) 0.49 (0.05 - 1.17) 46.23 (23.66 - 67.02) 29.01 (11.41 - 47.55)
Central 12.77 (10.99 - 14.52) 48.19 (45.06 - 50.85) 22.21 (15.17 - 29.53) 15.62 (10.65 - 21.01) 9.98 (3.27 - 18.77) 2.36 (0.66 - 4.65) 6.26 (1.27 - 13.53) 4.02 (0.75 - 8.98) 1.18 (0.18 - 2.59) 1.28 (0.20 - 2.74) 1.53 (0.13 - 3.60) 0.48 (0.04 - 1.14) 46.07 (23.64 - 66.64) 28.04 (11.04 - 45.90)
Southern 13.02 (11.28 - 14.73) 48.31 (45.43 - 50.65) 20.52 (12.46 - 29.48) 14.90 (9.24 - 21.30) 13.56 (4.21 - 25.70) 3.74 (0.99 - 7.70) 13.83 (3.41 - 28.54) 9.81 (2.36 - 20.20) 3.98 (0.49 - 9.37) 4.51 (0.57 - 10.61) 2.33 (0.16 - 5.75) 0.80 (0.06 - 1.93) 32.75 (14.20 - 54.46) 17.93 (6.32 - 31.88)
Tropical 12.95 (11.20 - 14.67) 49.49 (47.01 - 51.54) 19.63 (13.13 - 26.46) 13.52 (9.03 - 18.47) 10.53 (3.41 - 19.89) 2.46 (0.67 - 4.89) 8.24 (1.70 - 17.74) 5.25 (0.98 - 11.81) 1.93 (0.30 - 4.27) 2.03 (0.33 - 4.43) 1.47 (0.12 - 3.44) 0.46 (0.04 - 1.08) 45.24 (23.07 - 65.74) 26.79 (10.49 - 44.00)
World 20.58 (18.52 - 22.54) 52.61 (48.86 - 55.76) 34.73 (25.04 - 44.63) 24.75 (17.77 - 32.12) 8.43 (2.75 - 15.96) 2.05 (0.57 - 4.15) 5.57 (1.23 - 11.72) 4.16 (0.89 - 8.94) 1.20 (0.16 - 2.75) 1.49 (0.20 - 3.43) 3.09 (0.42 - 7.09) 1.10 (0.14 - 2.45) 25.99 (9.96 - 45.27) 13.61 (4.34 - 25.73)
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